Cancer

Intralipid 20% is a safe fat emulsion, composed of soybean oil (consisting of a mixture of long-chain triglycerides (C14-24) of predominantly unsaturated fatty acids), and egg phospholipids, can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response.

Doxorubicin liposome is a liposome-encapsulated form of doxorubicin hydrochloride (HY-15142). Doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic, is a potent human DNA topoisomerase I and topoisomerase II inhibitor. Compared to traditional doxorubicin, liposome encapsulation reduces its cardiotoxicity and prolongs its circulation time, thus enabling it to effectively target tumor tissue.

Paclitaxel liposome (Liposomal paclitaxel) is a liposome-encapsulated form of Paclitaxel (HY-B0015). Paclitaxel is a natural antitumor agent that stabilizes tubulin polymerization. Paclitaxel liposome exhibits reduced acute toxicity, prolonged circulating half-life of paclitaxel, and enhanced accumulation at tumor sites. Paclitaxel liposome can be used in cancer-related research.

Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia.

Cisplatin liposome is a liposome-encapsulated form of Cisplatin (HY-17394). Cisplatin (CDDP) is an anti-tumor chemotherapeutic agent that cross-links with DNA, causing DNA damage in cancer cells. Cisplatin liposome prolongs drug circulation time and slowly releases the drug, allowing it to accumulate in the tumor and exert its killing effect.

Mitoxantrone hydrochloride liposome is a liposome-encapsulated Mitoxantrone hydrochloride (HY-13502A) (a topoisomerase II inhibitor). Compared to regular Mitoxantrone hydrochloride, Mitoxantrone hydrochloride liposome enhances antitumor activity and prolongs drug circulation time in the body.

Bupivacaine liposome is a liposome-encapsulated form of Bupivacaine (HY-B0405). Bupivacaine is an NMDA receptor inhibitor. During the action potential, Bupivacaine blocks sodium channels, thereby inhibiting the generation and conduction of nerve impulses induced by painful stimuli. Bupivacaine liposome reduces the release rate of Bupivacaine, thus achieving a long-lasting pain relief effect.

Liposomal verteporfin is a liposome-encapsulated form of Verteporfin (HY-B0146). Verteporfin is a photosensitizer used in photodynamic therapy, which generates reactive oxygen species (ROS) upon irradiation at 690 nm to mediate photodynamic effects. Liposomal verteporfin can promote the release of Oxaliplatin (HY-17371) from endolysosomes via photochemical internalization (PCI), prolong the drug circulation time and enable sustained release, accumulate the drug in neovascular vessels, and enhance its cytotoxicity in tumor models. Liposomal verteporfin can be used in studies related to neovascular eye diseases and pancreatic cancer^[1][2][3].

Irinotecan liposome is a liposome-encapsulated form of Irinotecan hydrochlorid (HY-16562A) (a topoisomerase I inhibitor). Compared with Irinotecan, Irinotecan liposome enhances antitumor activity, reduces drug release rate, and avoids neutropenia.

Decitabine-Cisplatin Liposome is a delivery system that encapsulates Decitabine (HY-A0004) and Cisplatin (HY-17394) within tiny liposomes. The liposomes act as a protective layer, enhancing the absorption and bioavailability of both Decitabine and Cisplatin. The combination of Decitabine and Cisplatin synergistically induces Sox2 DNA demethylation and promotes Sox2 gene expression, making it a useful tool for gastric cancer research.